US 12,350,262 B2
Methods of treatment for cystic fibrosis
Weichao George Chen, San Diego, CA (US); Eric L Haseltine, Melrose, MA (US); Samuel Moskowitz, Waban, MA (US); Sarah Robertson, Somerville, MA (US); and David Waltz, Waban, MA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Aug. 31, 2022, as Appl. No. 17/899,660.
Application 17/899,660 is a continuation of application No. 16/629,472, granted, now 11,517,564, previously published as PCT/US2018/042486, filed on Jul. 17, 2018.
Claims priority of provisional application 62/657,508, filed on Apr. 13, 2018.
Claims priority of provisional application 62/633,024, filed on Feb. 20, 2018.
Claims priority of provisional application 62/623,748, filed on Jan. 30, 2018.
Claims priority of provisional application 62/562,029, filed on Sep. 22, 2017.
Claims priority of provisional application 62/533,392, filed on Jul. 17, 2017.
Prior Publication US 2023/0241045 A1, Aug. 3, 2023
Int. Cl. A61K 31/4439 (2006.01); A61K 31/404 (2006.01); A61K 31/443 (2006.01); A61K 31/47 (2006.01); A61P 11/00 (2006.01)
CPC A61K 31/4439 (2013.01) [A61K 31/404 (2013.01); A61K 31/443 (2013.01); A61K 31/47 (2013.01); A61P 11/00 (2018.01)] 4 Claims
 
1. A method of treating cystic fibrosis comprising administering to a patient in need thereof:
(a) 200 mg once daily of crystalline Form A of Compound I:

OG Complex Work Unit Chemistry
(b) 100 mg once daily of amorphous Compound II:

OG Complex Work Unit Chemistry
 and
(c) 150 mg per dose twice daily of amorphous Compound III:

OG Complex Work Unit Chemistry